Alachua, FL (PRWEB) January 09, 2013
AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today that AxoGen products will be featured in an educational forum at the combined 2013 Annual Meetings of The American Association for Hand Surgery (AAHS), The American Society for Peripheral Nerve (ASPN), and The American Society for Reconstructive Microsurgery (ASRM) in Naples, Florida, January 9-15.
“Surgeons are rethinking their approaches for peripheral nerve repair,” said Karen Zaderej, CEO for AxoGen. “AxoGen’s educational symposium and panel discussion will provide them with valuable insights on regenerative clinical solutions for their patients with peripheral nerve injuries.”
The Symposium and Panel Discussion entitled, “My New Treatment Algorithm: Peripheral Nerve Injuries”, will feature Ivica Ducic, MD, PhD as Moderator, and panelists Bauback Safa, MD, MBA, FACS, Patrick Basile, MD, and Erick DeVinney, BS, Director of Clinical and Translational Sciences for AxoGen. The event is scheduled for Thursday, January 10, 2013 from 1:00-2:00 pm and is open to all registered attendees of the AAHS meeting.
In addition, AxoGen will be exhibiting its technologies and products at Booth 42 at the AAHS, ASPN and ASRM meetings.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. For more information, visit our website at http://www.axogeninc.com.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.